Tempest Therapeutics (NASDAQ:TPST) Upgraded to “Sell” at Wall Street Zen

Wall Street Zen upgraded shares of Tempest Therapeutics (NASDAQ:TPST) to a sell rating in a research note published on Saturday morning,Wall Street Zen reports.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tempest Therapeutics in a report on Monday, July 13th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Tempest Therapeutics currently has a consensus rating of “Reduce”.

Tempest Therapeutics Trading Down 1.3%

TPST opened at $0.76 on Friday. The stock has a market cap of $12.84 million, a PE ratio of -0.18 and a beta of -1.73. Tempest Therapeutics has a 1 year low of $0.74 and a 1 year high of $12.23. The stock’s 50 day simple moving average is $0.95 and its 200-day simple moving average is $1.29.

Tempest Therapeutics (NASDAQ:TPST) last issued its earnings results on Thursday, August 13th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.04). Equities analysts forecast that Tempest Therapeutics will post -0.83 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Tempest Therapeutics stock. Squarepoint Ops LLC bought a new position in Tempest Therapeutics, Inc. (NASDAQ:TPST) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 30,900 shares of the company’s stock, valued at approximately $34,000. Squarepoint Ops LLC owned approximately 0.19% of Tempest Therapeutics at the end of the most recent reporting period. 22.52% of the stock is currently owned by institutional investors.

About Tempest Therapeutics

Tempest Therapeutics, Inc is a clinical-stage biotechnology company focused on developing small-molecule medicines for cancer. The company’s research combines tumor-targeted immune activation with approaches designed to disrupt tumor metabolism, with the goal of stimulating the immune system within the tumor microenvironment while limiting effects on healthy tissue.

Tempest’s pipeline has included TPST-1120, an oral, selective antagonist of peroxisome proliferator-activated receptor alpha (PPARα).